Angela Holtham - 01 Jan 2026 Form 3 Insider Report for ONCOLYTICS BIOTECH INC (ONCY)

Reporting relationship
Director
Issuer ticker
ONCY
Reported as of
01 Jan 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
02 Jan 2026, 16:30:33 UTC
Next SEC filing
03 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kirk Look, Attorney-in-Fact

Key filing fact

Angela Holtham filed Form 3 for ONCOLYTICS BIOTECH INC (ONCY) on 02 Jan 2026.

Key facts

  • This page summarizes Angela Holtham's Form 3 filing for ONCOLYTICS BIOTECH INC (ONCY).
  • 0 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 02 Jan 2026, 16:30.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002102488 Primary reporting owner

Holtham Angela

Relationship
Director
Address
C/O ONCOLYTICS BIOTECH INC., 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO
Signature
/s/ Kirk Look, Attorney-in-Fact
Signature date
02 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONCY holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
178,326
Date
01 Jan 2026
Ownership
Direct
ONCY holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,313
Date
01 Jan 2026
Ownership
By Spouse

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ONCY holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Jan 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
30,000
Exercise price
$3.40
Footnotes
F1, F2
ONCY holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Jan 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
30,000
Exercise price
$1.14
Footnotes
F1, F2
ONCY holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Jan 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
30,000
Exercise price
$2.76
Footnotes
F1, F2
ONCY holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Jan 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
30,000
Exercise price
$1.13
Footnotes
F1, F2
ONCY holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Jan 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
120,000
Exercise price
$1.08
Footnotes
F3
ONCY holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Jan 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
30,000
Exercise price
$1.08
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The stock option is fully vested and exercisable.

Footnote F2

The exercise price is listed in Canadian dollars.

Footnote F3

The stock option vests in three equal annual installments beginning on August 15, 2026.

Footnote F4

The stock option vests in full on August 15, 2026.

SEC remarks

Exhibit 24 - Power of Attorney.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .